CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: February 24, 2012
Result type: Reports
Project Number: SR0270-000
Product Line: Reimbursement Review

Generic Name: Rituximab

Brand Name: Rituxan

Manufacturer: Hoffman-La Roche Ltd.

Therapeutic Area: Granulomatosis with polyangiitis and microscopic polyangiitis

Indications: Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA), remission induction (adults)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: August 16, 2012

Recommendation Type: List with clinical criteria and/or conditions